 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ALG-020572 / Aligos Therap
Trial completion date, Trial termination, Trial primary completion date: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects (clinicaltrials.gov) - Apr 25, 2023
P1, N=40, Terminated, Sponsor: Aligos Therapeutics
Trial completion date: Feb 2023 --> Jul 2022 | Completed --> Terminated | Trial primary completion date: Feb 2023 --> Jul 2022; ALT flares suggestive of drug induced liver injury
- || ALG-020572 / Aligos Therap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects (clinicaltrials.gov) - Feb 8, 2023
P1, N=40, Completed, Sponsor: Aligos Therapeutics
Trial completion date: Feb 2023 --> Jul 2022 | Completed --> Terminated | Trial primary completion date: Feb 2023 --> Jul 2022; ALT flares suggestive of drug induced liver injury Active, not recruiting --> Completed | N=112 --> 40 | Trial completion date: Jun 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Feb 2023
- || ALG-020572 / Aligos Therap
Enrollment closed, Trial completion date, Trial primary completion date: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects (clinicaltrials.gov) - Mar 24, 2022
P1, N=112, Active, not recruiting, Sponsor: Aligos Therapeutics
Active, not recruiting --> Completed | N=112 --> 40 | Trial completion date: Jun 2022 --> Feb 2023 | Trial primary completion date: Jun 2022 --> Feb 2023 Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Jun 2022 | Trial primary completion date: Nov 2023 --> Jun 2022
- || ALG-020572 / Aligos Therap
Clinical, Adverse events: Aligos announced Tuesday it will discontinue development of ALG-020572 after a healthy volunteer was sent to the hospital to treat an adverse event. https://t.co/GR7HD2TEgk (Twitter) - Mar 22, 2022
- ALG-020576 / Aligos Therap, ALG-020572 / Aligos Therap
Incorporation of novel ASO chemistries significantly improves the potency and durability of HBV ASOs in the AAV-HBV mouse model (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1761;
Novel modifications of ALG-020576 significantly improved the in vivo depth and durability of HBsAg knockdown. Further investigations combining these chemistries are ongoing.
- ALG-020572 / Aligos Therap
Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1702;
Further investigations combining these chemistries are ongoing. ALG-020572 was safe and well tolerated with predictable PK properties when given to healthy subjects as single SC doses of up to 150 mg.
- ALG-020572 / Aligos Therap
[VIRTUAL] ALG-020572, A GALNAC-CONJUGATED ANTISENSE OLIGONUCLEOTIDE, DEMONSTRATES IN VIVO EFFICACY AND FAVORABLE PRECLINICAL PROFILE FOR THE TREATMENT OF CHRONIC HEPATITIS B () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1051;
ALG-020572 was safe and well tolerated with predictable PK properties when given to healthy subjects as single SC doses of up to 150 mg. The efficacy, hepatocyte targeting and a favorable PK profile of ALG- 020572 following SC administration warrants its advancement into clinical development as a potential treatment for CHB.
- ||| ALG-020572 / Aligos Therap
Enrollment open: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects (clinicaltrials.gov) - Sep 17, 2021
P1, N=112, Recruiting, Sponsor: Aligos Therapeutics
The efficacy, hepatocyte targeting and a favorable PK profile of ALG- 020572 following SC administration warrants its advancement into clinical development as a potential treatment for CHB. Not yet recruiting --> Recruiting
- ||| ALG-020572 / Aligos Therap
New P1 trial: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects (clinicaltrials.gov) - Aug 10, 2021
P1, N=112, Not yet recruiting, Sponsor: Aligos Therapeutics
- ALG-125755 / Aligos Therap, ALG-020572 / Aligos Therap
[VIRTUAL] Combination drug interactions of hepatitis B virus ( HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1097;
The HBV siRNA, ALG-125755, in combination with the ASO, ALG-020572, demonstrated additive to minor synergy in vitro and in vivo. Further investigation of the strategy to combine HBV siRNA and ASO compounds in CHB clinical trials is warranted.
- ALG-020572 / Aligos Therap
[VIRTUAL] ALG-020572, a next generation antisense oligonucleotide (ASO) with bridged nucleic acid chemistry, has a significantly improved preclinical profile () - Feb 9, 2021 - Abstract #APASL2021APASL_115;
- ALG-020572 / Aligos Therap
[VIRTUAL] DEVELOPMENT OF A BEST-IN-CLASS HBV ASO, ALG-020572, FOR THE TREATMENT OF CHRONIC HEPATITIS B () - Oct 11, 2020 - Abstract #AASLD2020AASLD_84;
Compared with a single ASO, a 1:1 combination of ALG-020572 and ALG-020576 offers enhanced in vivo potency, better genotypic coverage, a higher resistance barrier and a greater capacity to retain efficacy after HBV genome integration events. This regimen can also be combined with other anti-HBV agents.